Insights › Medicine & pharma › November 13, 2026
Medicine & pharma · Official intelligence

EMA recommends approval for Baxfendy (baxdrostat) for hypertension

European Union EMA (New human medicines) Published:

The EMA's CHMP adopted a positive opinion on 12 November 2026 recommending marketing authorization for Baxfendy (baxdrostat), developed by AstraZeneca AB. This medication containing baxdrostat is indicated for treating adult patients with arterial hypertension. It introduces a novel mechanism for blood pressure management.

Original source
Read the source — ema.europa.eu ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Medicine & pharma

See everything in Medicine & pharma →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.